Skip to main content

Table 1 Clinical and demographic features of TLE(HS) patients

From: Hippocampal gene expression dysregulation of Klotho, nuclear factor kappa B and tumor necrosis factor in temporal lobe epilepsy patients

Patients

Gender

Age (years)

Side of HS

Duration (years)

Last seizure (days before surgery)

TLE form

AED during surgery

TLE 01

F

34.6

L

28.6

nd

Familial

PHT

TLE 02

F

29.1

L

22.1

2

Sporadic

CBZ

TLE 03

F

23.8

R

22.3

7

Sporadic

CBZ

TLE 04

M

42.8

R

41.2

3

Sporadic

CBZ

TLE 05

M

41.2

L

34.2

5

Sporadic

CBZ

TLE 06

M

50.8

R

48.8

7

Sporadic

CBZ

TLE 07

M

12.7

L

9.7

3

Sporadic

CBZ, PHT

TLE 08

F

43.8

B(L)a

41.8

nd

Sporadic

CBZ, LTG

TLE 09

F

58.2

R

57.7

nd

Sporadic

OXC, VPA

TLE 10

F

54.9

L

50.9

nd

Sporadic

CBZ

TLE 11

F

32.1

L

31.6

nd

Familial

CBZ

TLE 12

F

38.3

L

37.0

2

Familial

OXC

TLE 13

F

54.1

L

53.3

nd

Sporadic

OXC, PHT

TLE 14

M

34.4

R

34.2

nd

Familial

OXC

  1. aThe hippocampal side was more affected when bilateral. When the patient’s last seizure was ‘nd’, the seizure most likely occurred over 7 days prior to surgery. TLE(HS), temporal lobe epilepsy associated with hippocampal sclerosis; M, male; F, female; B, bilateral; R, right; L, left; nd, not determined; AED, antiepileptic drug; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; LTG, lamotrigine; VPA, valproate.